Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Clinical trial NCT07434609 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07434609
- Sponsor
- Nanolattix Biotechnology Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2027-12-01
- Primary completion
- 2029-12-01
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.